Skip to main content
Log in

Thrombophilieabklärung im Hinblick auf östrogenhaltige Kontrazeptiva und Hormonersatztherapie

Thrombophilia, combined oral contraceptives and hormone replacement

  • Leitthema
  • Published:
Gynäkologische Endokrinologie Aims and scope

Zusammenfassung

Östrogenhaltige Kontrazeptiva und eine Hormonersatztherapie werden weltweit von Millionen Frauen genutzt. Obwohl die Verträglichkeit generell sehr gut ist, besteht ein Risiko venöser und arterieller Thromboembolien. Im vorliegenden Beitrag werden nicht nur häufige Thrombophilien beschrieben, sondern Risikofaktoren für Thrombosen und Lungenembolien erklärt. Das thromboembolische Risiko unter verschiedenen Präparaten wird diskutiert und Risikofaktoren unter einer entsprechenden Therapie beschrieben. Zudem werden Handlungsanweisungen für die tägliche Praxis präsentiert.

Abstract

Combined oral contraceptives (COC) and hormone replacement treatment are used by millions of women worldwide due to the reliable contraception and other health benefits they offer. Although side effects are few, the treatment puts patients at risk for venous and atrial thromboembolism. The following article describes common thrombophilic situations and risk factors for deep vein thrombosis and pulmonary embolism. The thromboembolic risk of patients treated with different types of estrogen-containing drugs is summarized and related risk factors discussed. Guidance for use in clinical practice is also provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2

Literatur

  1. Angelillo-Scherrer A, Nagler M (2016) Thrombophilieabklarung. Ther Umsch 73(10):626–634

    Article  PubMed  Google Scholar 

  2. Nygaard K, Brown G (1937) Essential thrombophilia, report of five cases. Arch Intern Med 59:82–106

    Article  Google Scholar 

  3. Egeberg O (1965) Inherited Antithrombin deficiency causing Thrombophilia. Thromb Diath Haemorrh 13:516–530

    Article  CAS  PubMed  Google Scholar 

  4. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C (1981) Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68(5):1370–1373

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Comp PC, Esmon CT (1984) Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 311(24):1525–1528

    Article  CAS  PubMed  Google Scholar 

  6. Dahlback B, Hildebrand B (1994) Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 91(4):1396–1400

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88(10):3698–3703

    Article  CAS  PubMed  Google Scholar 

  8. Garcia D, Erkan D (2018) Diagnosis and management of the Antiphospholipid syndrome. N Engl J Med 378(21):2010–2021

    Article  CAS  PubMed  Google Scholar 

  9. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306

    Article  CAS  PubMed  Google Scholar 

  10. Gando S, Levi M, Toh CH (2016) Disseminated intravascular coagulation. Nat Rev Dis Primers 2:16037

    Article  PubMed  Google Scholar 

  11. Bushman JE, Palmieri D, Whinna HC, Church FC (2000) Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res 24(7):559–565

    Article  CAS  PubMed  Google Scholar 

  12. Kyrle PA, Rosendaal FR, Eichinger S (2010) Risk assessment for recurrent venous thrombosis. Lancet 376(9757):2032–2039

    Article  PubMed  Google Scholar 

  13. Heit JA (2015) Epidemiology of venous thromboembolism. Nat Rev Cardiol 12(8):464–474

    Article  PubMed  PubMed Central  Google Scholar 

  14. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158(6):585–593

    Article  CAS  PubMed  Google Scholar 

  15. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F et al (2012) Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e496S

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Angelini D, Khorana AA (2017) Risk assessment scores for cancer-associated venous Thromboembolic disease. Semin Thromb Hemost 43(5):469–478

    Article  PubMed  Google Scholar 

  17. Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, Siragusa S, Palareti G (2010) Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 170(19):1710–1716

    Article  PubMed  Google Scholar 

  18. Nagler M, Ten Cate H, Prins MH, Ten Cate-Hoek AJ (2018) Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction. Res Pract Thromb Haemost 2(2):299–309

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Roach RE, Lijfering WM, Tait RC, Baglin T, Kyrle PA, Cannegieter SC, Rosendaal FR (2015) Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. J Thromb Haemost 13(10):1815–1822

    Article  CAS  PubMed  Google Scholar 

  20. Eichinger S, Weltermann A, Minar E, Stain M, Schonauer V, Schneider B, Kyrle PA (2004) Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 164(1):92–96

    Article  PubMed  Google Scholar 

  21. Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, Weltermann A, Wagner O, Kyrle PA (2003) D‑dimer levels and risk of recurrent venous thromboembolism. JAMA 290(8):1071–1074

    Article  CAS  PubMed  Google Scholar 

  22. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S et al (2006) D‑dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355(17):1780–1789

    Article  CAS  PubMed  Google Scholar 

  23. Ensor J, Riley RD, Moore D, Snell KI, Bayliss S, Fitzmaurice D (2016) Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open 6(5):e11190

    Article  PubMed  PubMed Central  Google Scholar 

  24. FSRH Guideline (2019) FSRH Guideline (January 2019) Combined Hormonal Contraception (Revision due by January 2024). BMJ Sex Reprod Health 45(Suppl 1):1–93

    Article  Google Scholar 

  25. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C (2009) Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 339:b2890

    Article  PubMed  PubMed Central  Google Scholar 

  26. Lekovic D, Miljic P, Dmitrovic A, Thachil J (2017) How do you decide on hormone replacement therapy in women with risk of venous thromboembolism? Blood Rev 31(3):151–157

    Article  PubMed  Google Scholar 

  27. van Vlijmen EF, Wiewel-Verschueren S, Monster TB, Meijer K (2016) Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 14(7):1393–1403

    Article  PubMed  Google Scholar 

  28. Garcia D, Akl EA, Carr R, Kearon C (2013) Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 122(5):817–824

    Article  CAS  PubMed  Google Scholar 

  29. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e691S–e736S

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Nagler.

Ethics declarations

Interessenkonflikt

M. Pollak und M. Nagler geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

B. Imthurn, Zürich

B. Toth, Innsbruck

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pollak, M., Nagler, M. Thrombophilieabklärung im Hinblick auf östrogenhaltige Kontrazeptiva und Hormonersatztherapie. Gynäkologische Endokrinologie 17, 139–147 (2019). https://doi.org/10.1007/s10304-019-0262-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-019-0262-y

Schlüsselwörter

Keywords

Navigation